Treatments with angiotensin antagonists that target TGFβ signalling as well as control blood pressure have been shown to prevent aortic dilation and the development of mitral valve prolapse in mice with MFS [136, 137]. This evidence concerns the gene TGFB1 and mitral valve prolapse.